Eylea HD vs Vabysmo access comparison: high-dose aflibercept vs faricimab payer positioning, Avastin step edits, dose-interval evidence, and buy-and-bill economics

Eylea HD (aflibercept 8 mg, Regeneron/Bayer) and Vabysmo (faricimab-svoa, Genentech/Roche) are the two newest intravitreal agents competing to displace Avastin and Eylea 2 mg as the standard of care in neovascular AMD, diabetic macular edema, and macular edema following retinal vein occlusion. Both offer extended dosing intervals that reduce injection burden, and both face the same payer barrier: Avastin-first step therapy that forces most patients through a cheaper off-label option before either drug is covered.

Retina practices are increasingly choosing between Eylea HD and Vabysmo as their preferred second-line agent. Spherix Global Insights reports that the last-five new Rx shares for both agents now surpass their overall brand shares, indicating continued growth. In an unconstrained scenario, ophthalmologists split their preference between the two, rating them similarly on duration of action, drying effect, and overall efficacy. Access — not clinical preference — is often the deciding factor.

This guide compares Eylea HD and Vabysmo across payer positioning, step-therapy hierarchies, HCPCS coding, buy-and-bill economics, dosing-interval durability, reauthorization criteria, and patient support programs.

Short-answer comparison

Payer step-therapy hierarchies: how Eylea HD and Vabysmo are tiered

Most payers apply the same three-tier anti-VEGF step-therapy framework to both Eylea HD and Vabysmo. The differences are in how payers rank the two drugs relative to each other — and those rankings are inconsistent across plans.

Typical tier structure

Under this structure, Eylea HD and Vabysmo are co-tiered at the same level: both require a documented Avastin trial and failure before coverage. Neither has a systematic advantage.

Where payers differentiate

UnitedHealthcare commercial (effective April 2026): Vabysmo is covered first-line with PA but no step through bevacizumab. Eylea HD requires PA but is also covered. For UHC Medicare Advantage, Vabysmo's position varies by indication: for nAMD, Eylea/Eylea HD/Pavblu are preferred over Vabysmo; for DME and RVO, Vabysmo requires a step through Eylea or Eylea HD.

UnitedHealthcare Community Plan (effective April 2025): Eylea HD (J0177) and Vabysmo (J2777) are both non-preferred. Preferred agents are Avastin, bevacizumab biosimilars, and certain ranibizumab biosimilars. Step therapy requires ≥ 3 months of preferred agent failure.

Atrio Health Plans (2026 Part B step therapy form): Eylea HD and Vabysmo are both in Group B (non-preferred), requiring 3 months of Group A (Avastin/bevacizumab biosimilar) trial and failure.

Blue Cross Blue Shield of Massachusetts (Policy 092): Eylea HD and Vabysmo are co-tiered at Step 2, both requiring prior Avastin failure.

Cigna (IP0540): Requires documented failure of repackaged bevacizumab before covering Eylea HD. Eylea HD patients must meet specific dosing criteria (not more frequent than q3w for 3 doses, then not more frequent than q7w).

CarelonRx (CC-0072): Both Eylea HD and Vabysmo are non-preferred, requiring prior Avastin failure. No differentiation between the two.

Access takeaway

Eylea HD and Vabysmo face essentially identical step-therapy barriers at most payers. The one meaningful difference: UHC commercial covers Vabysmo first-line (no Avastin step), while Eylea HD still requires PA. For UHC Medicare Advantage, the situation reverses — Eylea HD is preferred over Vabysmo for nAMD. Practices should verify payer-specific tiering at the point of prescribing rather than assuming parity.

HCPCS billing and coding comparison

J-code history matters for reimbursement

Eylea HD's permanent J-code (J0177) took effect April 1, 2024, replacing temporary codes (C9399/J3490/J3590). Spherix notes that the permanent J-code is expected to increase utilization tracking accuracy and may shift relative use between Eylea HD and Vabysmo now that billing is standardized.

Vabysmo has had J2777 since launch. Both codes are recognized by Medicare Part B and commercial payers.

Buy-and-bill economics

Key buy-and-bill considerations for both agents:

• Reimbursement tracks ASP, which updates quarterly. Practices must monitor ASP trends to maintain positive margins.
• Inventory cost: Both require refrigeration (2°C–8°C). Eylea HD is supplied in single-dose vials. Vabysmo is available in vials and prefilled syringes.
• Fewer injections = less revenue per patient-year: The extended dosing intervals that make both drugs clinically attractive also reduce the total number of billable injection encounters and drug administrations per year. Practices must weigh the lower injection frequency against the per-dose margin.

Dosing-interval durability: the key clinical differentiator

The primary clinical argument for both Eylea HD and Vabysmo over Eylea 2 mg is extended dosing intervals. Here is how the pivotal trial data compare:

Eylea HD — PULSAR (nAMD) and PHOTON (DME)

• PULSAR (nAMD, 1,009 patients): After 3 monthly doses, aflibercept 8 mg q12w and q16w were non-inferior to Eylea 2 mg q8w at week 48 (mean BCVA change: +6.7 and +6.2 letters vs. +7.6 letters). At week 96, 78% of Eylea HD patients maintained ≥ 16-week dosing intervals. At 3 years (156 weeks), the majority sustained visual gains while maintaining substantially extended intervals.
• PHOTON (DME, 658 patients): Aflibercept 8 mg q12w and q16w were non-inferior to Eylea 2 mg q8w at week 48 (+8.8 and +7.9 letters vs. +9.2 letters). At week 96, approximately 88% (9 out of 10) of Eylea HD patients had last assigned treatment intervals of q16w or longer. Some patients achieved dosing as infrequently as every 5 months (20 weeks).
• Label extension: The FDA label now allows extension to q20w after one year of successful response, making Eylea HD the only intravitreal agent with a label supporting up to 5-month intervals.

Vabysmo — TENAYA/LUCERNE (nAMD) and YOSEMITE/RHINE (DME)

• TENAYA/LUCERNE (nAMD): Vabysmo q8w and variable dosing (q8–q16w) were non-inferior to Eylea 2 mg q8w at year 1. Approximately 45% of patients achieved q16-week dosing at week 48.
• YOSEMITE/RHINE (DME): Non-inferior to Eylea 2 mg q8w. Extended-interval patients received fewer injections over 2 years while maintaining visual gains.
• BALATON/COMINO (RVO): Non-inferior to aflibercept at week 24 (BCVA change: +16.9 letters Vabysmo vs. +17.5 letters aflibercept in BALATON). April 2026 label update now allows continued treatment beyond 6 months for RVO.

Durability comparison for PA justification

For PA appeals, Eylea HD has a stronger evidence base for extreme interval extension (up to q20w), while Vabysmo has the mechanistic argument of dual Ang-2/VEGF-A inhibition. Both arguments are accepted by major payers when backed by OCT and visual acuity documentation.

Indication-specific coverage notes

nAMD

Both agents are widely covered. Coverage requires:

1. Diagnosis confirmed by fluorescein angiography and/or OCT
2. Prescribed by ophthalmologist or retina specialist
3. Step therapy met (Avastin trial and failure/intolerance at most plans)
4. No concurrent use of other VEGF inhibitors

DME

Coverage criteria mirror nAMD with additional diabetes documentation. Both agents require OCT-confirmed central-involved DME and documented diabetes mellitus diagnosis.

Macular edema following RVO

Vabysmo has a specific RVO indication with an updated label (April 2026) allowing treatment beyond 6 months. Eylea HD received FDA approval for RVO in November 2025. Both are covered, but Vabysmo's longer RVO track record with payers may result in smoother initial PA approval.

Diabetic retinopathy (DR)

Eylea HD is approved for DR. Vabysmo does not carry a standalone DR indication. For practices treating DR without DME, Eylea HD may have a labeling advantage.

ICD-10 codes

Reauthorization criteria

Both agents require reauthorization at 6–12 month intervals depending on the plan. Continuation requires:

1. OCT improvement: Reduction or maintenance of central subfield thickness vs. baseline
2. Visual acuity: Stable or improved BCVA (ETDRS or Snellen)
3. No disease progression: No worsening cystoid macular edema, subretinal fluid, or hemorrhage
4. Continued dosing at labeled intervals: Documentation that patient is being dosed per FDA-approved label
5. No concurrent VEGF inhibitor: Attestation that the anti-VEGF agent is being used as monotherapy

For patients switching between Eylea HD and Vabysmo, document the clinical rationale (e.g., inadequate drying on current agent, interval shortening required, adverse event) to support the reauthorization or switch PA.

Patient support programs

Eylea HD — Regeneron Access Solutions

• Benefit investigation: Verifies coverage, PA requirements, and cost-sharing
• PA and appeal support: Provides assistance with submissions
• Specialty pharmacy coordination: Identifies required specialty pharmacy
• Contact: (877) 877-2568

Vabysmo — Genentech Ophthalmology Access Solutions

• Benefit investigation: Verifies coverage, PA requirements, and cost-sharing
• PA assistance: Support for submissions and appeals
• Specialty pharmacy coordination: Identifies required specialty pharmacy
• Sample Avastin step-back appeal letter: Available at vabysmo-hcp.com, citing dual mechanism, extended interval data, and cost savings
• Contact: (833) 393-4363
• Copay programs: Separate product and administration copay programs for commercially insured patients
• Patient Foundation: Free Vabysmo for uninsured/underinsured patients meeting eligibility criteria

Key documentation checklist for PA submission

1. OCT report showing central subfield thickness and qualitative assessment
2. Visual acuity measurement (ETDRS or Snellen)
3. Diagnosis confirmation (nAMD: fluorescein angiography; DME: OCT + diabetes documentation; RVO: fundus exam + OCT)
4. ICD-10 diagnosis codes for the retinal condition
5. Prior anti-VEGF treatment history (drug name, dates, number of injections, response/failure documentation)
6. If step therapy: documentation of ≥ 3 months of Avastin trial with clinical rationale for switching
7. Prescriber specialty documentation (ophthalmologist or retina specialist)
8. No active ocular/periocular infection or inflammation
9. Attestation that the agent will not be combined with other VEGF inhibitors
10. Correct HCPCS code with unit count: J0177 × 8 units (Eylea HD) or J2777 × 60 units (Vabysmo)

Switching between Eylea HD and Vabysmo

Practices occasionally need to switch patients from one agent to the other. Common clinical and payer scenarios:

• Inadequate fluid control on Eylea HD: Document persistent intraretinal or subretinal fluid on OCT despite adequate dosing. Cite Vabysmo's dual Ang-2/VEGF-A mechanism as the clinical rationale for switching.
• Inadequate interval extension on Vabysmo: Document that the patient cannot extend beyond q8w on Vabysmo and cite Eylea HD's stronger extension data (up to q20w per label) as the rationale.
• Adverse events: Document intraocular inflammation, increased IOP, or other events specific to the current agent.
• Payer-mandated switch: If a plan changes its formulary tiering, document the plan requirement and the clinical appropriateness of the alternative.

For all switches, submit a new PA with updated OCT and visual acuity data, the clinical rationale for the switch, and prior treatment history on the current agent.

Sources

• FDA. Eylea HD (aflibercept) Injection 8 mg Prescribing Information. Updated 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761355s005lbl.pdf
• FDA. Vabysmo (faricimab-svoa) Prescribing Information. Updated April 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761235s000lbl.pdf
• Regeneron Pharmaceuticals. Three-Year Results for EYLEA HD in Patients with Wet AMD. February 8, 2025. https://investor.regeneron.com/news-releases/news-release-details/three-year-results-eylea-hdr-aflibercept-injection-8-mg-patients
• Regeneron Pharmaceuticals. EYLEA HD U.S. List Price (WAC). https://investor.regeneron.com/static-files/146d7101-2db1-4d35-b6d0-b9b94b11c6fb
• Genentech. Vabysmo Payer Coverage Guide. https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-payer-coverage.pdf
• CMS / National Government Services. Billing and Coding: Ranibizumab and biosimilars, Aflibercept, Aflibercept HD, Brolucizumab-dbll, Faricimab-svoa. Local Coverage Article A52451. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=52451
• UnitedHealthcare. Ophthalmologic VEGF Inhibitors Commercial Medical Benefit Drug Policy. Effective April 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/ophthalmologic-vegf-inhibitors.pdf
• Atrio Health Plans. Part B Prior Authorization Step Therapy Guidelines Ophthalmic VEGF Inhibitors. 2026. https://atriohp.com/media/2wjdocak/ophthalmic-vegf-inhibitors-part-b-step-therapy-pa-request-form-2026.pdf
• Aetna. Vascular Endothelial Growth Factor Inhibitors for Ocular Indications. CPB 0701. https://www.aetna.com/cpb/medical/data/700_799/0701.html
• Cigna Healthcare. Aflibercept Products Coverage Policy IP0540. https://static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ip_0540_coveragepositioncriteria_aflibercept.pdf
• Spherix Global Insights. Ophthalmologists Favor Genentech's Vabysmo and Regeneron's Eylea HD for DME Treatment Despite Payer Constraints. June 24, 2024. https://www.spherixglobalinsights.com/ophthalmologists-favor-genentechs-vabysmo-and-regenerons-eylea-hd-for-diabetic-macular-edema-treatment-despite-payer-constraints
• Brown DM et al. Aflibercept 8 mg in neovascular AMD: 156-week results from the PULSAR extension. Macula Society 2025.
• Brown DM et al. Aflibercept 8 mg in DME: 156-week results from the PHOTON extension. Macula Society 2025.
• Genentech. FDA Approves Updated VABYSMO Label for RVO. April 9, 2026. https://www.gene.com/media/statements/ps_040926